Drugs / 11C-PiB
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04768101 | Apr 2020 → Dec 2026 expected | Parkinson disease | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03757910 | Oct 2019 → Jan 2023 | Alzheimer disease | José A. Luchsinger | Terminated | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04263337 | Mar 2020 → Aug 2028 expected | brain injury | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02120664 | Apr 2014 → Sep 2015 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01826110 | Sep 2013 → Jul 2018 | Alzheimer disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03555292 | Jul 2017 → May 2021 | Parkinson disease | Oriental Neurosurgery Evidence-Based-Study Team | Unknown | No outcome recorded |
| Phase 2 | NCT00855868 | Mar 2009 → Jan 2011 | Alzheimer disease | Avid Radiopharmaceuticals | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04604587 | Oct 2020 → Jul 2023 | cerebral amyloid angiopathy, intracerebral hemorrhage | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04604600 | Sep 2020 → Jul 2023 | Alzheimer disease, vascular dementia | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03542656 | Sep 2014 → Feb 2016 | Alzheimer disease, cerebral amyloid angiopathy, intracerebral hemorrhage | National Taiwan University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06999434 Background | May 2025 → May 2030 expected | Alzheimer disease, multiple sclerosis, radiculopathy, spinal cord injury | Yale University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-PIB | “Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).” NCT03542656 ↗11“11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans” NCT03555292 ↗ “Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.” NCT04604600 ↗ “Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB” NCT04604587 ↗ |
| Known as | 11C-Pittsburgh compound B | “To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with...” NCT03555292 ↗ |
| Modality | Diagnostic / imaging agent | “To perform PET scans with \[11C\]PIB” NCT01826110 ↗ |
| Route | Intravenous | “555 MBq (15 mCi), IV injection, single dose \[11C\]-PIB” NCT00855868 ↗ |